ESTRO 2025 - Abstract Book

S2036

Clinical - Urology

ESTRO 2025

Center of Gdańsk, Gdansk, Poland. 7 Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdansk, Poland. 8 III Radiotherapy Clinic, Maria Skłodowska -Curie National Research Institute of Oncology, Gliwice, Poland. 9 Faculty of Medicine,, Jan Dlugosz University in Czestochowa,, Czestochowa, Poland. 10 Department of Radiotherapy, Department of Radiotherapy, Czestochowa, Poland. 11 Radiotherapy Department, Holycross Cancer Center, Kielce, Poland. 12 Collegium Medicum, Jan Kochanowski University of Kielce, Kielce, Poland. 13 Brachytherapy Department, Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland. 14 Radiotherapy Department, Katowickie Centrum Onkologii, Katowice, Poland. 15 Radiotherapy Department, Subcarpathian Cancer Center, Brzozow, Poland. 16 Radiotherapy Clinic, Gdynskie Centrum Onkologii, Gdynia, Poland. 17 Department of External Beam Radiotherapy, Regional Cancer Center Copernicus Memorial Hospital of Lodz, Lodz, Poland Purpose/Objective: Retrospective evaluation of the outcome of elderly men (over 80 years old) treated with radical radiotherapy due to prostate cancer (PC) in 22 Polish cancer centres. Material/Methods: Study inclusion criteria: age over 80 years old at the time of PC diagnosis, radical RT after 2014, and at least 1 year of follow-up (in alive patients). Data regarding co-morbidities, risk group (low – LR, favourable intermediate – FIR, unfavourable intermediate – UIR, high – HR), RT schema, toxicity (RTOG scale), biochemical failure (BF), local/regional/distant relapse (LR/RR/DR) and overall (OS), biochemical failure free (BFFS) and metastases-free (MFS) survival was collected. Kaplan-Meier survival analysis, log rank test, Cox regression model and Chi2 tests were used in statistical analysis. Results: Study inclusion criteria were met in 953 men with PC, with a mean age of 83 years at diagnosis (IQR 80-85). Co morbidities were evaluated in 804 and only 6.5% had no co-morbidities, while 9.8% lung diseases, 47.1% heart diseases (with 52.2% of them having stroke/heart attack/pacemaker medical records). The study included patients with 7.1%LR, 17.9%FIR, 15.2%UIR and 59.7%HR disease. The majority (89.4%) were in good performance status (ECOG 0-1). RT was delivered conventionally fractionated (CRT, fraction dose,fd=2Gy) in 19.1%, moderately hypofractionated (MHRT,fd 2.1-3.4Gy) in 63.6%, stereotactic (SRT,fd6-7.25Gy) in 4.4%, RT+brachytherapy boost (RTBT) in 11.0%, and brachytherapy(BT) in 1.9%, respectively. Toxicity is presented in Table1.

The median FU was 37months(IQR 13.4-72.8) and the 5-year OS was 71% (Table2). BF/LF/RF/DF was diagnosed in 9.3%,2.8%,3.3% and 6.0% of patients, respectively. Cardiac co-morbidities didn't influence OS(p=0.24).